Amgen ( AMGN) said late Thursday it is seeking to raise $2.5 billion in a convertible debt offering.

The biotech firm said it intends to use proceeds from the offering to repurchase up to $650 million of its own common stock, and for general corporate purposes, including acquisitions.

Amgen is in the midst of completing a $16 billion acquisition of Immunex ( IMNX), which includes payment of about $2.5 billion in cash. The deal is expected to close in the second half of the year.

Amgen had $2.6 billion in cash on hand at the end of 2001.

The offering calls for the sale of 30-year, zero-coupon senior notes convertible into Amgen common shares.

If you liked this article you might like


Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio